Pharvaris NV reported highly positive topline results from its late-stage clinical trial for deucrictibant XR, an oral drug for hereditary angioedema (HAE) prevention. The trial met all primary and secondary efficacy endpoints with an excellent safety profile, leading to a significant stock jump and paving the way for regulatory applications in early 2027.
Pharvaris NV announced overwhelmingly positive topline results from its CHAPTER-3 Phase 3 clinical trial for deucrictibant XR, an oral drug designed to prevent hereditary angioedema (HAE) attacks. The drug demonstrated an 83% reduction in mean monthly attack rate compared to placebo, with a favorable safety profile, meeting all primary and secondary endpoints. This is a major catalyst for PHVS, as it significantly de-risks their lead pipeline candidate and positions them for regulatory submissions in early 2027. The short-term impact is a substantial increase in stock price, reflecting increased investor confidence in the drug's market potential. Long-term, successful approval and commercialization could establish PHVS as a significant player in the HAE treatment market, potentially challenging existing therapies. The key opportunity for traders is the continued upward momentum as the market digests the strong data and anticipates future regulatory milestones.